XBiotech Inc.
XBITXBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases.
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
14dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
XBIT Earnings Report
FQ end 2026-06
How XBIT's past catalysts played out
Natrunix
Rheumatoid Arthritis
514G3 (2 mg/kg) plus standard IV antibiotic treatment
Staphylococcus Aureus Bacteremia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Natrunix | Phase 2 | Rheumatoid Arthritis | - | - |
514G3 (2 mg/kg) plus standard IV antibiotic treatment | Phase 2 | Staphylococcus Aureus Bacteremia | - | - |
Rheumatoid Arthritis
1 drug in this indication
Staphylococcus Aureus Bacteremia
1 drug in this indication
Pancreatic Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in XBiotech Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in XBiotech Inc.'s (XBIT) pipeline across Phase 2. Its lead program is Natrunix (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is XBiotech Inc.'s next FDA catalyst?→
XBiotech Inc.'s (XBIT) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track XBIT biotech catalysts?→
Add XBIT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow XBiotech Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.